목적: Patients with chronic rhinosinusitis (CRS) reportedly experience improved sleep quality after dupilumab therapy. Concurrent CRS and obstructive sleep apnea (OSA) cases are not rare, and CRS seemingly raises nasal resistance. It was hypothesized that improved sleep quality by dupilumab therapy in CRS patients may be due to lowered nasal resistance and subsequent improvement of unrecognized comorbid OSA. 방법:Patients with concurrent CRS and OSA were recruited. CRS was confirmed by a physician based on anterior rhinoscopy and computed tomography. OSA was established using standard polysomnography. Nasal resistance was measured invasively with transnasal pressure and flow data collected during normal respiration in the supine position. Several subjective and objective parameters for CRS and OSA were also measured before and after dupilumab therapy. 결과:The trial was terminated prematurely because it was difficult to find CRS patients with high nasal resistance in whom to test the hypothesis. Also, results in the first five participants did not support the hypothesis. Subjective and objective measures for CRS and nasal resistance values were improved with dupilumab therapy in CRS patients with nasal polyps. However, apnea severity and sleep-related subjective parameters did not change. In the patients with CRS without nasal polyps, no significant changes in either CRS or OSA-related measures were observed. 결론:Improved sleep reported in previous dupilumab studies is unlikely to be due to reduced nasal resistance or reduction in OSA.